Vikram Purohit
Stock Analyst at Morgan Stanley
(1.54)
# 3,515
Out of 5,124 analysts
161
Total ratings
37.5%
Success rate
-6.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Equal-Weight | $86 → $92 | $98.77 | -6.85% | 25 | Dec 8, 2025 | |
| CMPS COMPASS Pathways | Maintains: Overweight | $10 → $11 | $6.90 | +59.42% | 2 | Nov 5, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $36.31 | -6.36% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $67.30 | +17.38% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $3.49 | +68.77% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $4.09 | +22.25% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $213.24 | +17.24% | 19 | May 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $182.64 | +4.03% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $5.40 | +66.67% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $30.80 | +0.65% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $134.86 | -88.14% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $29.04 | -65.56% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $9.03 | -33.55% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $14.41 | +191.46% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $77.81 | -47.31% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $11.00 | +263.64% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.24 | +480.36% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $17.88 | +112.53% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $8.81 | +127.01% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $18.71 | -46.55% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.00 | +2,100.00% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $19.17 | +4.33% | 2 | Aug 5, 2020 |
Incyte
Dec 8, 2025
Maintains: Equal-Weight
Price Target: $86 → $92
Current: $98.77
Upside: -6.85%
COMPASS Pathways
Nov 5, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $6.90
Upside: +59.42%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $36.31
Upside: -6.36%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $67.30
Upside: +17.38%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $3.49
Upside: +68.77%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $4.09
Upside: +22.25%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $213.24
Upside: +17.24%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $182.64
Upside: +4.03%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $5.40
Upside: +66.67%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $30.80
Upside: +0.65%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $134.86
Upside: -88.14%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $29.04
Upside: -65.56%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $9.03
Upside: -33.55%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $14.41
Upside: +191.46%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $77.81
Upside: -47.31%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $11.00
Upside: +263.64%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.24
Upside: +480.36%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $17.88
Upside: +112.53%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $8.81
Upside: +127.01%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $18.71
Upside: -46.55%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.00
Upside: +2,100.00%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $19.17
Upside: +4.33%